---
title: "reast Cancer Subtypes as Defined by the Estrogen R | Sutter Health"
description: "Breast Cancer Subtypes as Defined by the Estrogen Receptor (ER), Progesterone Receptor (PR), and the Human Epidermal Growth Factor Receptor 2 (HER2)"
url: "https://www.sutterhealth.org/research/publications/breast-cancer-subtypes-as-defined-by-the-estrogen-1055312635"
---

1.  [Home](https://www.sutterhealth.org/) /
2.  [Research](https://www.sutterhealth.org/research) /
3.  [Research publications](https://www.sutterhealth.org/research/publications) /
4.  reast Cancer Subtypes as Defined by the Estrogen R

# Breast Cancer Subtypes as Defined by the Estrogen Receptor (ER), Progesterone Receptor (PR), and the Human Epidermal Growth Factor Receptor 2 (HER2) among Women with Invasive Breast Cancer in California

1999-2004. Breast J. November/December 2009;15(6):593-602.

_Breast Journal_

2009-12-20

## Abstract

Breast cancer research examining either molecular profiles or biomarker subtypes has focused on the estrogen receptor negative/progesterone receptor negative/human epidermal growth factor receptor 2 negative (ER-/PR-/HER2-) and ER-/PR-/HER2+ subtypes. Less is known about the epidemiology or clinical outcome of the other subtypes. This study examines the eight combinations of ER/PR/HER2 in patients with invasive breast cancer. The 5-year relative survival and the distribution among demographic, socioeconomic, and tumor characteristics of each of the subtypes are examined. Using the California Cancer Registry, 61,309 women with primary invasive breast cancer were classified according to ER/PR/HER2 status. Five-year relative survival was computed for the eight subtypes. Bivariate analyses were used to assess the distribution of cases across all subtypes. Multivariate logistic regression was used to compute the adjusted odds of having one of the five subtypes with the best and worst survival. Survival varied from 96% (ER+/PR+/HER2-) to 76% (ER-/PR-/HER2+ and ER-/PR-/HER2-). The four subtypes with the poorest survival were all ER negative. Women who were younger than age 50, non-Hispanic black or Hispanic, of the lowest SES groups, and had stage IV tumors that were undifferentiated were overrepresented in ER-/PR-/HER2+ and triple negative (ER-/PR-/HER2-) subtypes. Asian Pacific Islanders had increased odds (OR = 1.41; 95% confidence interval \[CI\] = 1.26-1.57) of having the ER-/PR-/HER2+ subtype. Stage III tumors (OR = 1.25; 95% CI = 1.08-1.44) and stage IV tumors (OR = 1.58; 95% CI = 1.27-1.98) had higher odds than stage I tumors of being ER-/PR-/HER2+. Stage IV tumors (OR = 0.54; 95% CI = 0.44-0.67) strongly decreased the odds of the ER-/PR-/HER2- subtype. Poorly differentiated and undifferentiated tumors were over 20 times as likely as well-differentiated tumors of being ER-/PR-/HER2- or ER-/PR-/HER2+. There are considerable differences in survival, demographics, and tumor characteristics among the eight subtypes. We recommend reporting breast cancer as an ER/PR/HER2 subtype and precisely documenting demographic and tumor characteristics.

[PubMed abstract](http://www.ncbi.nlm.nih.gov/pubmed/19764994)

![Carol Parise, Ph.D.](https://www.sutterhealth.org/static/images/sutter-fallback-image-3-4.jpg)

Carol Parise, Ph.D.

Principal investigator

[View profile](https://www.sutterhealth.org/research/investigators/carol-parise-phd-1049681206)

## Research topics

-   [All Cancer](https://www.sutterhealth.org/research-search-results?query=%22%5C%22All+Cancer%5C%22%22)

## Related publications

[View all publications](https://www.sutterhealth.org/research-search-results?verticalKey=research_publication)

-   Publication
    
    ### [Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers](https://www.sutterhealth.org/research/publications/breast-cancer-survival-defined-by-the-er-pr-her2-1055312621)
    
    Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers. Parise CA, Caggiano V. J Cancer Epidemiol. 2014;2014:469251. doi: 10.1155/2014/469251. Epub 2014 May 26
    
    Breast Journal
    
    2014 May 26
    
-   Publication
    
    ### [Light at night and health: the perils of rotating shift work.](https://www.sutterhealth.org/research/publications/light-at-night-perils-of-rotating-shifts-1055312837)
    
    Schernhammer ES, Thompson CA.
    
    Occup Environ Med. 68(5):310-1. doi: 10.1136/oem.2010.058222. Epub 2010 Oct 4.
    
    2011 May 01
    
-   Publication
    
    ### [Meta-analysis in asymmetric catalysis. Influence of chelate geometry on the roles of PN chelating ligands.](https://www.sutterhealth.org/research/publications/meta-analysis-in-asymmetric-catalysis-influence-o-1055312709)
    
    Org Biomol Chem. 2013 Jul 28;11(28):4591-601. doi: 10.1039/c3ob40360b. Epub 2013 May 2. Meta-analysis in asymmetric catalysis. Influence of chelate geometry on the roles of PN chelating ligands. Carroll MP1, Guiry PJ, Brown JM. Author information 1School of Chemistry and Chemical Biology, Centre for Synthesis and Chemical Biology, University College Dublin, Dublin 4, Ireland.
    
    Org Biomol Chem. 2013 Jul 28;11(28):4591-601. doi: 10.1039/c3ob40360b. Epub 2013 May 2. Meta-analysis in asymmetric catalysis. Influence of chelate geometry on the roles of PN chelating ligands. Carroll MP1
    
    Guiry PJ
    
    Brown JM. Author information 1School of Chemistry and Chemical Biology
    
    Centre for Synthesis and Chemical Biology
    
    University College Dublin
    
    Dublin 4
    
    Ireland.
    
    2013 Jul 28
    
-   Publication
    
    ### [Oxalate transport in cultured porcine renal epithelial cells.](https://www.sutterhealth.org/research/publications/oxalate-transport-in-cultured-porcine-renal-epithe-1055312722)
    
    T R Wandzilak 1, L Calo, S D'Andre, A Borsatti, H E Williams
    
    T R Wandzilak 1
    
    L Calo
    
    S D'Andre
    
    A Borsatti
    
    H E Williams
    
    1992 Jul 20
    
-   Publication
    
    ### [Sociopsychological tailoring to address colorectal cancer screening disparities: a randomized controlled trial](https://www.sutterhealth.org/research/publications/sociopsychological-tailoring-to-address-colorectal-1055312656)
    
    Sociopsychological tailoring to address colorectal cancer screening disparities: a randomized controlled trial. Jerant A1, Kravitz RL, Sohler N, Fiscella K, Romero RL, Parnes B, Tancredi DJ, Aguilar-Gaxiola S, Slee C, Dvorak S, Turner C, Hudnut A, Prieto F, Franks P.
    
    Ann Fam Med. 2014 May-Jun;12(3):204-14. doi: 10.1370/afm.1623. Sociopsychological tailoring to address colorectal cancer screening disparities: a randomized controlled trial.
    
    2014 May 30
    

[View all publications](https://www.sutterhealth.org/research-search-results?verticalKey=research_publication)

```json
{"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]}
```

```json
{"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/publications/breast-cancer-subtypes-as-defined-by-the-estrogen-1055312635#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Research publications","item":"https://www.sutterhealth.org/research/publications"},{"@type":"ListItem","position":4,"name":"reast Cancer Subtypes as Defined by the Estrogen R"}]}
```

```json
{"@context":"https://schema.org","@type":"MedicalScholarlyArticle","@id":"https://www.sutterhealth.org/research/publications/breast-cancer-subtypes-as-defined-by-the-estrogen-1055312635#medicalscholarlyarticle","name":"Breast Cancer Subtypes as Defined by the Estrogen Receptor (ER), Progesterone Receptor (PR), and the Human Epidermal Growth Factor Receptor 2 (HER2) among Women with Invasive Breast Cancer in California","headline":"reast Cancer Subtypes as Defined by the Estrogen R","abstract":"Breast cancer research examining either molecular profiles or biomarker subtypes has focused on the estrogen receptor negative/progesterone receptor negative/human epidermal growth factor receptor 2 negative (ER-/PR-/HER2-) and ER-/PR-/HER2+ subtypes. Less is known about the epidemiology or clinical outcome of the other subtypes. This study examines the eight combinations of ER/PR/HER2 in patients with invasive breast cancer. The 5-year relative survival and the distribution among demographic, socioeconomic, and tumor characteristics of each of the subtypes are examined. Using the California Cancer Registry, 61,309 women with primary invasive breast cancer were classified according to ER/PR/HER2 status. Five-year relative survival was computed for the eight subtypes. Bivariate analyses were used to assess the distribution of cases across all subtypes. Multivariate logistic regression was used to compute the adjusted odds of having one of the five subtypes with the best and worst survival. Survival varied from 96% (ER+/PR+/HER2-) to 76% (ER-/PR-/HER2+ and ER-/PR-/HER2-). The four subtypes with the poorest survival were all ER negative. Women who were younger than age 50, non-Hispanic black or Hispanic, of the lowest SES groups, and had stage IV tumors that were undifferentiated were overrepresented in ER-/PR-/HER2+ and triple negative (ER-/PR-/HER2-) subtypes. Asian Pacific Islanders had increased odds (OR = 1.41; 95% confidence interval [CI] = 1.26-1.57) of having the ER-/PR-/HER2+ subtype. Stage III tumors (OR = 1.25; 95% CI = 1.08-1.44) and stage IV tumors (OR = 1.58; 95% CI = 1.27-1.98) had higher odds than stage I tumors of being ER-/PR-/HER2+. Stage IV tumors (OR = 0.54; 95% CI = 0.44-0.67) strongly decreased the odds of the ER-/PR-/HER2- subtype. Poorly differentiated and undifferentiated tumors were over 20 times as likely as well-differentiated tumors of being ER-/PR-/HER2- or ER-/PR-/HER2+. There are considerable differences in survival, demographics, and tumor characteristics among the eight subtypes. We recommend reporting breast cancer as an ER/PR/HER2 subtype and precisely documenting demographic and tumor characteristics.","description":"Breast Cancer Subtypes as Defined by the Estrogen Receptor (ER), Progesterone Receptor (PR), and the Human Epidermal Growth Factor Receptor 2 (HER2)","keywords":["All Cancer"],"datePublished":"2009-12-20","url":"https://www.sutterhealth.org/research/publications/breast-cancer-subtypes-as-defined-by-the-estrogen-1055312635","inLanguage":"en-US","identifier":[{"@type":"PropertyValue","propertyID":"PMID","value":"19764994"}],"sameAs":["https://pubmed.ncbi.nlm.nih.gov/19764994/"],"isPartOf":{"@type":"Periodical","name":"Breast Journal"},"sourceOrganization":{"@type":"MedicalOrganization","name":"Sutter Institute for Medical Research"},"about":[{"@type":"DefinedTerm","name":"All Cancer","url":"https://www.sutterhealth.org/research-search-results?facets=%5B%7B%22i%22%3A%22c_researchTopics.name%22%2C%22v%22%3A%5B%22All+Cancer%22%5D%7D%5D&verticalKey=research_publication"}],"mainEntityOfPage":{"@type":"WebPage","@id":"https://www.sutterhealth.org/research/publications/breast-cancer-subtypes-as-defined-by-the-estrogen-1055312635","breadcrumb":{"@id":"https://www.sutterhealth.org/research/publications/breast-cancer-subtypes-as-defined-by-the-estrogen-1055312635#breadcrumblist"}}}
```
